Erratum: Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease: (Cardiovasc Drugs Ther 2010 24 93 DOI 10.1007/s10557-005-3117-9);Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 19, Issue 4, 2005, Pages 277-281

  Lekakis, John P ^a   Protogerou, Athanassios ^a   Papamichael, Christos ^a   Vamvakou, Georgia ^a   Iconomidis, Ignatios ^a   Fici, Francesco ^b   Mavrikakis, Myron ^a  

^a ALEXANDRA HOSPITAL   (Greece)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Atenolol; Brachial artery; Coronary artery disease; Endothelial function; Nebivolol

Indexed keywords

ATENOLOL; NEBIVOLOL;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY ENDOTHELIUM; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; MALE; PRIORITY JOURNAL; VASODILATATION;

EID: 28844434160     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6187-2     Document Type: Erratum

References (27)

1. Quyyumi AA. Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am J Med 1998;105:32S-39S.
2. Vita JA, Keany JF Jr. Endothelial function. A barometer for cardiovascular risk? Circulation 2002;106:640-642.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilatory dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
4. Perticone F, Ceravolio R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-196.
5. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002;40:505-510.
6. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol. A third-generation beta-blocker that augments vascular nitric oxide release. Endothelial beta (2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-684.
7. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press 2004:13(Suppl. 1):2-16.
8. Cominacini L, Pasini FA, Garbin U, et al. Nebivolol and its 4-keto derivatives increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838-1844.
9. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized, double-blind, crossover study. Circulation 2001;104:511-514.
10. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-1241.
11. Neunteufl T, Heher S, Katzeschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-210.
12. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002;39:257-265.
13. Lekakis J, Papamichael C, Barbaki P, et al. Comparison of low-density lipoprotein cholesterol lowering by pravastatin to <100 mg/dl versus >100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus. Am J Cardiol 2002;89:857-860.
14. Cockroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature. Evidence for an L-arginine/NO - dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-1071.
15. Chlopicki S, Kozlovski VI, Gryglewski RJ. NO-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5 HT receptors. J Physiol Pharmacol 2002;53:615-624.
16. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204.
17. Galderisi M, Cicala S, D'Errico A, de Divitiis O, de Simone G. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004;22(11):2201-2208.
18. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-1319.
19. Kuvin J, Patel R, Sliney K, et al. Peripheral vascular endothelial function testing as a non-invasive indicator of CAD. J Am Coll Cardiol 2001;38:1843-1849.
20. Gokce N, Keany JF Jr, Frei B, et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with CAD. Circulation 1999;99:3234-3240.
21. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003;23:615-621.
22. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000;50:377-379.
23. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of vasodilatory beta-adrenoreceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999;33:467-471.
24. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation 2003;107:2747-2752.
25. Gokce N, Keany JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: A prospective study. Circulation 2002;105:1567-1572.
26. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003;108:2093-2098.
27. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215-225.